ViiV's HIV drug Tivicay gets preliminary EU nod
This article was originally published in Scrip
ViiV Healthcare's oral integrase strand transfer inhibitor (ISTI) Tivicay (dolutegravir) has been recommended for approval in the European Union. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) said it should be authorized for use in combination with other antiretroviral medicines to treat HIV-infected adults and adolescents over 12 years of age. A final decision is expected in early 2014.